- Founder(s): Thomas Lindhorst and Birgit Werner
- Established: April 2016
- CEO(s): Thomas Lindhorst and Birgit Werner
- Employees: 2
- Financial Data: Privately funded
- Website: ugisense.com
The proprietary antisense technology developed by UGISense AG overcomes the drawbacks of standard antisense technologies. Together with industrial partners, they develop drugs for so far non-treatable diseases. Indication areas are oncology, metabolic diseases and muscular dystrophies.
Munich offers a great network and stimulating biotech community where they are located.